@article{e244634f330741ffa60612b6ba6c82cf,
title = "Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST",
abstract = "Background: Nonmotor symptoms (NMSs) of Parkinson's disease (PD) impair health-related quality of life. Objectives: To identify changes in NMSs during 52 weeks in Japanese PD patients exhibiting motor fluctuations. Methods: In PD patients with ≥1 NMS and wearing-off, changes in total/subscore of the Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part I and 8-item PD Questionnaire were assessed. Group-based trajectory models were used to characterize longitudinal patterns of MDS-UPDRS Part I. Results: Data from 996 patients were analyzed. MDS-UPDRS Part I subscores for cognitive function decreased linearly over time. Total and subscores for apathy and lightheadedness on standing significantly deteriorated with fluctuations, whereas other subscores fluctuated without significant deterioration. Changes in the MDS-UPDRS Part I total score correlated with changes in the 8-item PD Questionnaire total score. Based on group-based trajectory models, longitudinal pattern analysis of MDS-UPDRS Part I scores yielded the following 3 separate groups: unchanged (63.8%), deteriorated (20.1%), and improved (16.2%). The improved group had significantly more NMSs at baseline, significantly higher MDS-UPDRS Part I/8-item PD Questionnaire total scores, and modified Hoehn and Yahr scores, and had received treatment for NMSs. The multivariate analysis revealed significant associations between severe motor disability and receiving any treatment for NMSs at baseline and improvement of MDS-UPDRS Part I total scores. Conclusions: Changes in MDS-UPDRS Part I scores were variable and related to changes in health-related quality of life in PD patients with motor fluctuations.",
keywords = "Japan, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's disease, nonmotor symptoms, observational study",
author = "{the J-FIRST group} and Hirohisa Watanabe and Hidemoto Saiki and Chiu, {Shih Wei} and Takuhiro Yamaguchi and Kenichi Kashihara and Yoshio Tsuboi and Masahiro Nomoto and Nobutaka Hattori and Tetsuya Maeda and Yasushi Shimo",
note = "Funding Information: H.W. received lecture fees from Otsuka Pharmaceutical, Kyowa Kirin, Takeda Pharmaceutical, Sumitomo Dainippon Pharma, FP Pharmaceutical, Eisai, Daiichi Sankyo, and Novartis Pharma, and grants from Otsuka Pharmaceutical and FUJIFILM RI Pharma H.S. received lecture fees from Sumitomo Dainippon Pharma, Otsuka Pharmaceutical, Kyowa Kirin, Medtronic Inc., Takeda Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma, M3 Inc., Eisai, GlaxoSmithKline, and Nihon Medi‐Physics; honoraria from Elsevier Japan and Japan Medical Journal; research support from Kyowa Kirin; and grants from Otsuka Pharmaceutical and Nippon Boehringer Ingelheim S.C. received lecture fees and honoraria from Kyowa Kirin T.Y. owns stock in Statcom, received lecture fees from Kowa, Nippon Zoki Pharmaceutical, Japan Tobacco, Taiho Pharmaceutical, and EPS Corporation; honoraria from Ono Pharmaceutical; research support from Kyowa Kirin; and grants from EPS Corporation, Nifix, Kowa, MSD, Pharma Consulting Group, Statcom, Sumitomo Dainippon Pharma, Ono Pharmaceutical, AC Medical, A2 Healthcare, FMD K&L Japan, CAC Croit, Japan Tobacco, Japan Media Corporation, Medidata Solutions, and Luminary Medical. K.K. received lecture fees from Boehringer Ingelheim, Kyowa Kirin, Novartis Pharma, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, FP Pharmaceutical, Nihon Medi‐Physics, and Eisai; and honoraria from Sumitomo Dainippon Pharma. Y.T. received lecture fees from Japan Blood Products Organization, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Meiji Seika Pharma, Ono Pharmaceutical, Nihon Medi‐Physics, Dainippon Sumitomo Dainippon Pharma, Novartis Pharma, Otsuka Pharmaceutical, and Kyowa Kirin; and research support from Otsuka Pharmaceutical, Kaketsuken, Eisai, Nippon Boehringer Ingelheim, Daiichi Sankyo, Japan Blood Products Organization, Kyowa Kirin, Sumitomo Dainippon Pharma, and Tsumura & Co. M.N. received consulting fees from Hisamitsu Pharmaceutical and Sumitomo Dainippon Pharma; grants from the Japanese Ministry of Health, Labour and Welfare; and honoraria from Sumitomo Dainippon Pharma, Otsuka Pharmaceutical, Kyowa Kirin, Novartis Pharma, and Ono Pharmaceutical. N.H. received consulting fees from GlaxoSmithKline, AbbVie, Eisai, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, Kyowa Kirin, Hisamitsu Pharmaceutical, Meiji Seika Pharma, Ono Pharmaceutical and FP Pharmaceutical; lecture fees from MSD, Eli Lilly Japan, Eisai, FP Pharmaceutical, Otsuka Pharmaceutical, Tsumura & Co., Kyowa Kirin, GlaxoSmithKline, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Nihon Medi‐Physics, Novartis Pharma, Pfizer Japan, Nippon Boehringer Ingelheim, Sumitomo Dainippon Pharma, and Daiichi Sankyo; honoraria from FP Pharmaceutical, Novartis Pharma, Kyowa Kirin, and AbbVie; research support from Otsuka Pharmaceutical; and grants from Astellas Pharma, Eisai, GlaxoSmithKline, Dainippon Sumitomo Pharma, Takeda Pharmaceutical, Novartis Pharma, Pfizer Japan, Kyowa Kirin, Medtronic, Nippon Boehringer Ingelheim, Boston Scientific, Kissei Pharmaceutical and Otsuka Pharmaceutical. T.M. received lecture fees from Kyowa Kirin, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, and Novartis Pharma. Y.S. received lecture fees from Medtronic, Sumitomo Dainippon Pharma, Kyowa Kirin, Otsuka Pharmaceutical, Novartis Pharma, Boston Scientific, and Nihon Medi‐Physics; research support from Kyowa Kirin; and grants from Medtronic, Kyowa Kirin, Nippon Boehringer Ingelheim, Boston Scientific Corporation, and Kissei Pharmaceutical. Financial Disclosures for Previous 12 Months: Funding Information: This study was sponsored by Kyowa Kirin Co. Ltd., Editorial support was provided by Keyra Martinez Dunn, MD, of Edanz Medical Writing on behalf of EMC K.K., which was funded by Kyowa Kirin Co. Ltd. H.W., K.K., and T.M. received lecture fees from Kyowa Kirin Co. Ltd. H.S. and S.C. received lecture fees and honoraria from Kyowa Kirin Co. Ltd. T.Y. received research support from Kyowa Kirin Co. Ltd. Y.T. received lecture fees and research support from Kyowa Kirin Co. Ltd. M.N. received honoraria from Kyowa Kirin Co. Ltd. N.H. received consulting fees, lecture fees, honoraria, and grants from Kyowa Kirin Co. Ltd. Y.S. received lecture fees, research support, and grants from Kyowa Kirin Co. Ltd. Funding Sources and Conflict of Interest: Publisher Copyright: {\textcopyright} 2020 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.",
year = "2020",
month = may,
day = "1",
doi = "10.1002/mdc3.12939",
language = "English",
volume = "7",
pages = "431--439",
journal = "Movement Disorders Clinical Practice",
issn = "2330-1619",
publisher = "John Wiley and Sons Ltd",
number = "4",
}